US FDA designates Celltrion's Yuflyma as an interchangeable biosimilar to Humira
Celltrion, Inc. announced that the US Food and Drug Administration (FDA) has designated Yuflyma (adalimumab-aaty), as an interchangeable biosimilar to Humira (adalimumab). Yuflyma is an FDA-approved, high-concentration (100mg/mL) and citrate-free …